Core Oncology has developed a large number of highly flexible, yet tightly controlled study designs which have been popular with regulatory authorities and ethics committees alike.
Core Oncology flexible protocols improve the effectiveness and efficiency of early phase oncology drug development. Core Oncology believes that many of the standard study designs used today in oncology drug development are too restrictive. Such studies hinder full evaluation of the safety and potential tumour activity of the drug, while taking far too long to reach their endpoints. Time, cost and disruption caused by numerous protocol amendments can be avoided using the Core Oncology methodology.
We believe that our expertise in developing flexible, well-structured and disciplined study designs help our Sponsors obtain more relevant data within a shorter timeframe and at a lower cost.
